Intracranial tumor operation
Conditions
Interventions
Propofol (Contral):Patients in group C were given propofol 2-2.5mg/kg during anesthesia induction and IV propofol 4-10 mg/kg /h during anesthesia maintenance.
Remazolam Group Low Dose (R1):According to the instructions for use, remazolam was given 0.3 mg/kg during anesthesia induction and 1.0mg /kg/h intravenously during anesthesia maintenance.
Remazolam Medium Dose (R2):According to the instructions for use, remazolam was given 0.3 mg/kg during anesthesia induction and 2.0mg /kg/h intravenously during anesthesia maintenance.
Remazolam Group High Dose (R3):According to the instructions, remazolam was given 0.3 mg/kg during anesthesia induction and 3.0mg /kg/h intravenously during anesthesia maintenance.
Sponsors
Guiyang Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Study intends to include healthy patients aged 18-60 years old; 2. Bmi 18-28kg/m^2; 3.ASA grade I-III; 4. No abnormality in hearing and memory function; 5. No history of long-term use of sedative drugs.
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications to general anesthesia; 2.Patients who have used narcotic analgesics within 24 hours or used narcotic drugs within 5 days, long-term (continuous or intermittent) use of benzodiazepines sleeping pills, opioid analgesics; 3. Have a history of serious cardiovascular disease (such as myocardial ischemia, heart failure and arrhythmia); Patients with angina pectoris due to insufficient coronary blood supply to the heart (unstable angina), or who have had a myocardial infarction within the last 6 months; 4. Patients with hypertension whose blood pressure was not satisfactorily controlled by antihypertensive medication (recumbent systolic blood pressure =180 mmHg, and/or diastolic blood pressure =110 mmHg during the screening period); 5. Pregnant or lactating women; 6. Liver and kidney insufficiency; 7. Patients with mental system diseases (schizophrenia, mania, bipolar disorder, insanity, etc.), drug history and cognitive dysfunction; 8. Participated in drug clinical trials as a subject within the last 3 months; 9. Patients who are deemed unfit by the investigator to participate in this trial; 10. Patients whose subjects refuse to participate in clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean arterial pressure and Heart rate;Onset time of administration;Patient recovery time;Inflammatory markers (NSE, S100ß, GFAP, IL-6, CRP, TNF-a); | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions;Evaluation of intraoperative awareness; | — |
Countries
China
Contacts
Public ContactJingjiew Wang
Guiyang Second People's Hospital
Outcome results
None listed